What type of study is this?

This is a Validation Study study.

December 8, 2025BloodOpen Access

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

View Full Paper

Ask AI

Bookmark

Higher MCL35 scores from tumor tissue correlated with inferior progression-free survival in Mantle Cell Lymphoma patients.
Gene expression profiling in liquid biopsies effectively stratified patients, reflecting tumor proliferation levels.
The deep generative ML model improved transcriptomic predictions from cfDNA, suggesting non-invasive assessment benefits.
Results highlight the promise of liquid biopsies as a tool for risk stratification in Mantle Cell Lymphoma diagnosis.

Authors

JSJoseph G. Schroers‐MartinPalo Alto University MEMohammad Shahrokh EsfahaniStanford Medicine AAAsh A. AlizadehCalifornia Institute for Regenerative Medicine

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis found non-invasive risk stratification methods improve prognostic accuracy in Mantle Cell Lymphoma, indicating potential for liquid biopsies.

Cite This Study

Schroers‐Martin et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d77d https://doi.org/10.1182/blood-2025-1789

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis found non-invasive risk stratification methods improve prognostic accuracy in Mantle Cell Lymphoma, indicating potential for liquid biopsies.

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

Key Points

Discussion

Implication

Cite This Study

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider